En Es
Categories

Industry News

AI-Enabled Diagnostic Testing Could Become More Accurate and Reliable than Current Tests

By Labmedica International staff writers
07 Nov 2022

Image: Numares AXINON System (Photo courtesy of Numares)

An expanded collaboration between two industry leaders will pave the way for the development of AI-enabled diagnostic testing that is more accurate and reliable than current U.S. tests for patients with chronic diseases, including kidney, cardiovascular, liver and neurologic conditions.


The expanded collaboration builds on Mayo Clinic’s (Rochester, MN, USA) clinical research support for Numares Health (Regensburg, Germany) to include an innovative convertible equity investment. Numares is a health care company using AI-enabled technology to develop novel diagnostic tests designed to give physicians a better tool to care for their patients with conditions related to metabolic dysfunction, such as chronic kidney, liver and cardiac diseases. These assessments also may allow for early intervention to slow disease progression. Enabled by machine learning, this innovative testing modality being researched uses distinct and transparent algorithms combining multiple biomarkers to measure disease progression more accurately in patients with chronic diseases.


Numares develops advanced tests to aid in diagnosis and measurement of disease progression by applying machine learning to metabolomics and other biomarkers. The company has developed the AXINON System that uses next-generation nuclear magnetic resonance spectroscopy to evaluate metabolic constellations and a proprietary magnetic group signaling (MGS) technology that enables the spectroscopy. Two Numares tests are expected to gain FDA 510(k) approval early next year, one assessing kidney function (AXINON GFR(NMR) test) and one measuring cardiac risk (AXINON lipoFIT test).


"The expanded research collaboration and financial investment in Numares will help us further understand this new and potentially disruptive test modality, develop new diagnostic tests and enable Mayo Clinic to better serve our patients and physicians," said Dr. Allan Jaffe, a cardiologist and the former chair of Mayo Clinic's division of clinical core laboratory services in the department of laboratory medicine and pathology.


"This significant expansion of our long-standing collaboration with Mayo Clinic has brought us one step closer to our shared goal of improving patient care," said Winton Gibbons, Numares chief executive officer. "The new investment accelerates our development pipeline and drives research collaborations that fulfill critical unmet medical needs with new clinical utility. With the additional investment, we've enhanced our ability to target our focus on delivering this patient care technology to U.S. physicians as an improved diagnostic tool for their use."


Related Links:
Mayo Clinic 
Numares Health 



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

25 Jan 2023
Global Diagnostic Imaging Services Market Driven by Rising Prevalence of Chronic Diseases
The global diagnostic imaging services market was valued at USD 40.80 billion in 2021 and is expected to register a CAGR of 5.8% during the forecast period 2022-2030 to reach USD 67.94 billion in 2030, driven by the rising prevalence of chronic diseases, increasing elderly population, and rapid technological advancements in the healthcare diagnostic industry.
Read More
25 Jan 2023
Global Endoscopy Equipment Market Driven by Growing Hospital Investment in Advanced Instruments
The global endoscopy equipment market is projected to register a CAGR of 7% from USD 28.9 billion in 2022 to USD 40.6 billion by 2027, driven by increasing demand for endoscopy to diagnose and treat target diseases, rising investments, funds, and grants by governments and other organizations across the world, and growing focus by hospitals on investing in technologically-advanced endoscopy instruments and expanding endoscopy units.
Read More
25 Jan 2023
Point-of-Care Glucose Testing Market to Reach Almost USD 6 Billion by 2032
The global point-of-care (POC) glucose testing market is projected to register a CAGR of 4.3% during the forecast period from 2022 to 2032 to reach USD 5.8 billion by 2032, driven by a rise in the geriatric population, speed & precision of POC screening, increased adoption of electronic medical information, and the higher risk of COVID-19-related mortality associated with diabetes.
Read More
24 Jan 2023
Carolina Liquid Chemistries and Diazyme Enter Into Partnership
Carolina Liquid Chemistries, Corp. (CLC, Greensboro, NC, USA) and Diazyme Laboratories, Inc. (San Diego, CA, USA) have entered into a partnership to expand the test menu on the Diazyme DZ-Lite c270 benchtop clinical chemistry analyzer, allowing it to run both special and routine chemistries.
Read More
23 Jan 2023
Mindray Defibrillators Amongst the World’s First to Receive MDR Clearance
Mindray has received the CE marking for its defibrillation product family under the European Union's newest Medical Device Regulation (MDR). With the new rule tightening the controls for defibrillation devices, Mindray has become among the first manufacturers in the world to earn MDR accreditation for product quality and effectiveness.
Read More
23 Jan 2023
Siemens Launches Centre of Excellence for Immunoassay Instrument R&D in Ireland
Siemens Healthineers has launched a Center of Excellence for Immunoassay Instrument Research and Development (R&D) in Swords, Ireland. The new center will focus on unlocking breakthrough innovations in laboratory instruments used to detect infectious diseases, cancer and blood disorders.
Read More
20 Jan 2023
Global Intensive Care Unit (ICU) Equipment Market Driven By Increasing Neurological Diseases
The global intensive care unit (ICU) equipment market was valued at USD 6.6 billion in 2021 and is estimated to register a CAGR of 3.9% from 2022 to 2031 to reach USD 9.6 billion by 2031, driven primarily by a rise in the prevalence of neurological diseases.
Read More
20 Jan 2023
Bayer Acquires Imaging AI Platform Provider in the UK
Bayer (Leverkusen, Germany) has acquired Blackford Analysis Ltd. (Edinburgh, UK), a global strategic imaging AI platform and solutions provider. The acquisition is part of Bayer's strategy to drive innovation in radiology, including the development and adoption of AI within the clinical workflow, with the goal to ultimately improve patient care and advance the company’s position in digital medical imaging.
Read More
16 Jan 2023
Medlab Middle East Sees 100% Increase in Exhibitor Numbers
Medlab Middle East, the MENA region’s largest medical laboratory exhibition and congress, has sold out its exhibitor space ahead of the show, which returns to the Dubai World Trade Centre from February 6 to 9, 2023.
Read More
Copyright © 2000-2023 TradeMed.com. All rights reserved. | Terms And Conditions